Open an account

Oculis Holding AG

OCS · NASDAQ

$7.49+$0.17 (+2.32%)TodayMarket closed ·
Prev close $7.32

About OCS

Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The company is headquartered in Zug, Zug and currently employs 60 full-time employees. The company went IPO on 2023-03-03. The firm is focused on the development of eye disease treatment for ophthalmology. The company includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The firm have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.

Employees
60
Headquarters
Zug, Zug
Listed
Mar 3, 2023
Sector
Health Care
Industry
Pharmaceuticals
Website
oculis.com

OCS key statistics

Market cap
462.37M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
327.91K
Volume
318.69K
Open price
$7.29
High today
$7.79
Low today
$7.29
52 Week high
$34.48
52 Week low
$7.11

Oculis Holding AG (OCS) at a glance

Oculis Holding AG (OCS) last traded at $7.49, with a market cap of 462.37M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $7.29 and $7.79. The current price is 2.8% above the day's low and 3.9% below its high.

Volume so far is 318.69K shares, in line with the average of 327.91K shares a day.

Over the past year Oculis Holding AG has ranged from $7.11 to $34.48, and now sits 1% of the way up that range.

Oculis Holding AG met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.16 per share against an estimate of -$0.4069.

The average analyst price target is $39.78, 431.1% above the current price, from 9 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 9 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 12 analystsAvg $39.78
Low
$32.32
Now
$7.49
High
$47.25

OCS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 22.2% on average.

  1. Q3 FY24: reported -$0.48 per share against an estimate of -$0.4861
  2. Q4 FY24: reported -$0.67 per share against an estimate of -$0.4414
  3. Q1 FY25: reported -$0.69 per share against an estimate of -$0.4417
  4. Q2 FY25: reported -$0.49 per share against an estimate of -$0.4689
  5. Q3 FY25: reported -$0.32 per share against an estimate of -$0.4281
  6. Q4 FY25: reported -$0.42 per share against an estimate of -$0.4269
  7. Q1 FY26: reported -$0.49 per share against an estimate of -$0.4232
  8. Q2 FY26: reported -$0.16 per share against an estimate of -$0.4069

OCS news

  • Press releaseGlobe Newswire

    Oculis Reports Q2 2026 Financial Results and Provides Company Update

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS

  • Press releasePRNewswire

    Oculis Holding AG (OCS) Securities Fraud Investigation - Levi & Korsinsky

  • Press releaseBusiness Wire

    OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.